Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective.
BACKGROUND
There are over 40000 ischaemic strokes annually in Canada, which result in significant morbidity, mortality and burden to the healthcare system. A recent, large clinical trial has evaluated tissue plasminogen activator (t-PA) intravenously for the treatment of acute ischaemic stroke with promising outcomes but with an increased risk of symptomatic intracranial haemorrhage.


OBJECTIVE
To compare clinical and economic outcomes of intravenous t-PA therapy (0.9 mg/kg, to a maximum of 90 mg, initiated within 3 hours of stroke onset) versus no t-PA for acute ischaemic stroke based on the outcomes achieved in the National Institute of Neurological Disorders and Stroke (NINDS) trial.


METHODS
A Markov model depicting the natural lifetime course after an initial acute ischaemic stroke. On the basis of this model, a simulated trial compared no t-PA with t-PA.


METHODS
A hypothetical cohort of 1000 patients with acute ischaemic stroke.


METHODS
Canadian healthcare system.


METHODS
Total acute stroke and post-stroke treatment costs and cumulative quality-adjusted life-years (QALYs).


RESULTS
For a hypothetical cohort of 1000 patients, the estimated lifetime stroke costs were 103100000 Canadian dollars (SCan) [1999 values) in the t-PA arm ($Can103100 per patient) compared with SCan106900000 in the no t-PA arm ($Can106900 per patient), yielding a lifetime cost difference of $Can3800000 in favour of t-PA versus no t-PA (SCan3800 per patient). In the hypothetical cohort, t-PA treatment resulted in 13 130 QALYs versus 9670 QALYs with no t-PA treatment. This translated into a net benefit of 3460 additional QALYs per 1000 patients (3.46 QALYs per patient). No treatment, outcome or economic variables influenced the model outcome.


CONCLUSIONS
From the standpoint of cost effectiveness, treatment of acute ischaemic stroke with intravenous t-PA is an economically attractive strategy.
Sinclair
S E
SE
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
Frighetto
L
L
Loewen
P S
PS
Sunderji
R
R
Teal
P
P
Fagan
S C
SC
Marra
C A
CA
D002170:Canada / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use*; D006760:Hospitalization / Q000191:economics; D006801:Humans; D008390:Markov Chains; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D019057:Quality-Adjusted Life Years; D010959:Tissue Plasminogen Activator / Q000191:economics / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator